
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals
By Maggie FickLONDON (Reuters) - AstraZeneca (NASDAQ:AZN) said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.Chief Executive Pascal Soriot was in Beijing and met with the city’s mayor to reveal the investment, along w ...